Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 16/20 | 0.48 |
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 6/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585784 | 1.00 | ADRB2 (0.60) | ADRB2HTR2CHTR2AKCNH2HTR2B | |
| SCHEMBL5585823 | 1.00 | ADRB2 (0.60) | ADRB2HTR2CHTR2AKCNH2HTR2B | |
| SCHEMBL6204964 | 0.89 | ADRB2 (0.58) | ADRB2HTR2CHTR2AKCNH2HTR2B | |
| SCHEMBL15219155 | 0.86 | HTR2C (0.48) | ADRB2HTR2CHTR2AKCNH2HTR2B | |
| SCHEMBL5585597 | 0.80 | HTR2C (0.46) | ADRB2HTR2CHTR2AKCNH2HTR2B | |
| SCHEMBL5585599 | 0.80 | HTR2C (0.46) | ADRB2HTR2CHTR2AKCNH2HTR2B | |
| SCHEMBL21262057 | 0.77 | HTR2C (0.50) | HTR2CHTR2AKCNH2HTR2BPIM1 | |
| SCHEMBL22578950 | 0.77 | HTR2C (0.50) | HTR2CHTR2AKCNH2HTR2BPIM1 | |
| SCHEMBL5586006 | 0.77 | HTR2C (0.51) | ADRB2HTR2CHTR2AKCNH2HTR2B | |
| SCHEMBL5585870 | 0.77 | HTR2C (0.51) | ADRB2HTR2CHTR2AKCNH2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | claimed |
| JP-2005529926-A | — | — | 2005-10-06 | — | — | JP | claimed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | claimed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | claimed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232814-A1 | Novel compounds and their use | GPR119, FABP4, MC4R | ADRB2 63/4885HTR2C 233/4885HTR2A 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.